Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
about
Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.Outcome after intensive reinduction therapy and allogeneic stem cell transplant in paediatric relapsed acute myeloid leukaemia.Enhancing acute myeloid leukemia therapy - monitoring response using residual disease testing as a guide to therapeutic decision-making.Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol.Gene mutational pattern and expression level in 560 acute myeloid leukemia patients and their clinical relevance.Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell TransplantationCharacterization of children with FLT3-ITD acute myeloid leukemia: a report from the AIEOP AML-2002 study group.
P2860
Q36919799-42877509-E39E-4DDC-B893-C33A072CA01BQ38821563-9121A2D1-9D05-44AA-A80E-06F02A49BAAFQ39285841-109FF6B9-1DEF-41D0-963A-CB7437CAACB8Q39420815-B057F681-CEBD-4504-AAF0-1903828DD453Q40316983-D3FB8856-2D1A-4512-ABBB-BB344BD5D7BDQ41498838-D882E3F8-A83D-4DF9-A9B7-02FDB260C00AQ42711146-7681499E-865E-484E-945D-59A1F5BC2EF5Q48159392-A01DEBEA-E628-4185-82C5-6515BB42101F
P2860
Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Minimal residual disease monit ...... r treatment of patients with t
@nl
Minimal residual disease monit ...... ) RUNX1-RUNX1T1 rearrangement.
@en
type
label
Minimal residual disease monit ...... r treatment of patients with t
@nl
Minimal residual disease monit ...... ) RUNX1-RUNX1T1 rearrangement.
@en
prefLabel
Minimal residual disease monit ...... r treatment of patients with t
@nl
Minimal residual disease monit ...... ) RUNX1-RUNX1T1 rearrangement.
@en
P2093
P2860
P50
P1433
P1476
Minimal residual disease monit ...... ) RUNX1-RUNX1T1 rearrangement.
@en
P2093
Barbara Buldini
Carmelo Rizzari
Claudia Tregnago
Elena Manara
Maria Caterina Putti
Riccardo Masetti
Roberto Rondelli
Valzerda Beqiri
P2860
P304
P356
10.3324/HAEMATOL.2014.114579
P577
2014-12-05T00:00:00Z